mRNA cancer vaccine shows protection at 5-year follow-up, Moderna and Merck say

Moderna and Merck report that a custom mRNA cancer vaccine, intismeran autogene (mRNA-4157 or V940), combined with Keytruda, reduced the risk of cancer recurrence and death by nearly 50 percent over five years in a Phase 2 trial. The vaccine is tailored to each patient's unique cancer, targeting up to 34 unique markers of their mutated cancer cells. The results are consistent with previous analyses at two and three years, but full data is yet to be published.